Advanced Cell Technology Comments on U.S. Appeals’ Court’s Dismissal Ruling in Case Challenging Federal Funding of Embryonic Stem Cell Research  
8/27/2012 10:17:09 AM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”)(OTCBB: ACTC), a leader in the field of regenerative medicine, today issued a statement on the U.S. Appeals Court’s ruling, upholding a lower court’s dismissal of the case, “Sherley v. Sebelius,” 11-5241, U.S. Court of Appeals for the District of Columbia Circuit (Washington), on the permissibility of federal funding of embryonic stem cell research.